Afatinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 20 mg, 30mg, 40 mg
Reference Brands: Gilotrif (USA), Giotrif (EU/UK)
Category: Oncology Cancer Care
Afatinib is a small-molecule tyrosine kinase inhibitor that irreversibly blocks signaling by the epidermal growth factor receptor (EGFR/ErbB) family (including EGFR, HER2, HER4). It is used primarily for adult patients with metastatic non-small-cell lung cancer (NSCLC) whose tumours harbour certain EGFR gene mutations, and also for squamous NSCLC progressing after platinum-based chemotherapy. Afatinib is available in Tablets and strengths such as 20 mg, 30mg, 40 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Afatinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Afatinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Afatinib is used for the treatment of non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR) gene. It is also indicated for metastatic NSCLC and certain cases of squamous cell carcinoma of the lung. Afatinib helps block cancer cell growth by inhibiting EGFR and other related receptor tyrosine kinases.
Afatinib is made from the active ingredient afatinib dimaleate, which is an irreversible inhibitor of the ErbB family of receptors, including EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4).
The trade name of Afatinib is Gilotrif in the United States and Giotrif in the European Union and the United Kingdom.
Afatinib (Gilotrif/Giotrif) is developed and marketed by Boehringer Ingelheim Pharmaceuticals.
The generic name is Afatinib Dimaleate.
The brand names are Gilotrif and Giotrif.
Afatinib is manufactured by Boehringer Ingelheim at its facilities in Germany and the United States under strict international quality and regulatory standards.
Related Products
Momelotinib
Strength:
100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Ojjaara (USA)
View Details
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Nintedanib
Strength:
100 mg, 150 mg
Form: Capsules
Reference Brands: Ofev (USA, EU), Vargatef (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
